<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="./10_1101_606715v1/results/search/disease/results.xml">
  <result pre="witnessed outbreaks of myriad RNA viruses, including West Nile Virus," exact="severe acute respiratory syndrome" post="(SARS) coronavirus, chikungunya virus, Ebola virus, Zika virus, and"/>
  <result pre="including West Nile Virus, severe acute respiratory syndrome (SARS) coronavirus," exact="chikungunya" post="virus, Ebola virus, Zika virus, and most recently the"/>
  <result pre="example, cocktails used to treat human immunodeficiency virus infection and" exact="hepatitis" post="C virus (HCV) infection include synthetic nucleoside analogues targeting"/>
  <result pre="fast and/or producing high levels of proteins, as observed in" exact="cancer" post="cells or in virus-infected cells. Seminal studies from the"/>
  <result pre=", LaFemina, R. , et al. ( 2003). Inhibition of" exact="hepatitis" post="C virus RNA replication by 2’-modified nucleoside analogs. J."/>
  <result pre=", and Stephan, C. ( 2018). Protease inhibitor therapy for" exact="hepatitis" post="C virus-infection. Expert Opin. Pharmacother. 19, 577– 587. OpenUrl"/>
  <result pre=", and Bull, R. A. ( 2015). Inhibitors of the" exact="hepatitis" post="C virus polymerase, mode of action and resistance. Viruses"/>
  <result pre="Single-cell analysis and stochastic modelling unveil large cell-to-cell variability in" exact="influenza" post="A virus infection. Nat. Commun. 6, 8938. OpenUrl CrossRef"/>
  <result pre="S. ( 2009). Antiviral combination therapy for treatment of chronic" exact="hepatitis" post="B, hepatitis C, and human immunodeficiency virus infection. In"/>
  <result pre="2009). Antiviral combination therapy for treatment of chronic hepatitis B," exact="hepatitis" post="C, and human immunodeficiency virus infection. In Antiviral Strategies."/>
  <result pre="inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in" exact="cancer" post="therapy. Curr. Med. Chem. 16, 3081– 3092. OpenUrl CrossRef"/>
  <result pre="Advances in the development of nucleoside and nucleotide analogues for" exact="cancer" post="and viral diseases. Nat. Rev. Drug Discov. 12, 447–"/>
  <result pre="et al. ( 2003). Coronavirus as a possible cause of" exact="severe acute respiratory syndrome." post="Lancet 361, 1319– 1325. OpenUrl CrossRef PubMed Web of"/>
  <result pre=", and Bloom, J. D. ( 2018). Extreme heterogeneity of" exact="influenza" post="virus infection in single cells. Elife 7, e32303. OpenUrl"/>
  <result pre="E. ( 2014). HSP90 inhibitors: current development and potential in" exact="cancer" post="therapy. Recent Pat. Anticancer Drug Discov. 9, 1– 20."/>
  <result pre="B. S. ( 2012). Nucleoside, nucleotide, and non-nucleoside inhibitors of" exact="hepatitis" post="C virus NS5B RNA-dependent RNA- polymerase. J. Med. Chem."/>
  <result pre="Xie, M. Y. , et al. ( 2006). Inhibition of" exact="hepatitis" post="C replicon RNA synthesis by beta-D-2’-deoxy-2’-fluoro-2’-C-methylcytidine: a specific inhibitor"/>
  <result pre="C replicon RNA synthesis by beta-D-2’-deoxy-2’-fluoro-2’-C-methylcytidine: a specific inhibitor of" exact="hepatitis" post="C virus replication. Antivir. Chem. Chemother. 17, 79– 87."/>
  <result pre="exhibits potent antitumor activity and a superior safety profile for" exact="cancer" post="therapy. Mol. Cancer Ther. 11, 475– 484. OpenUrl Abstract"/>
 </snippets>
</snippetsTree>
